Veeva Systems

VEEV

Market cap $47.1B

VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.

Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Deep, industry-specific agents planned for availability starting this December PLEASANTON, Calif. , Oct. 14, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI Agents are planned for availability starting December 2025 for commercial and across R&D and quality in 2026.

There aren't many guarantees in life, but the stock market's ability to deliver competitive returns over long periods may be one of them. So, despite some volatility related to the threat of tariffs and other factors this year, it's still a good idea to invest in stocks.

In the closing of the recent trading day, Veeva Systems (VEEV) stood at $286.59, denoting a -3.98% move from the preceding trading day.

Veeva Systems, Inc. (VEEV) shares soar nearly 1,000% since Big Money's first outlier buy in 2015.

Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthcare market is expected to reach $504B by 2032, driven by an aging population, medical data explosion, job shortages, and consumer demand for self-care technology. Healthcare companies are increasingly deploying AI in drug discovery, diagnostics, imagery, robot-assisted surgery, and hospital administration.

The Investment Committee give you their top stocks to watch for the second half.

The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest stock spotlight.